VAREX IMAGING
VREX Healthcare Medical Devices
VAREX IMAGING’s revenue for fiscal 2025 (year ended September 2025) was $844.6 million, up 4.14% from fiscal 2024. In the quarter to June 2026, revenue grew 3.69%, EPS grew 117.2%, free cash flow grew 757.1% and total debt fell 5.55%, each against the same quarter a year earlier.
Follow VREX
VAREX IMAGING (VREX) P/E ratio
As of 16 October 2026, VAREX IMAGING (VREX) trades at a P/E ratio of 34.7×. Over the past ten years it has ranged from 0.0× (June 2026) to 221× (April 2020); the current reading is higher than 76% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 15.5× | (43.54%) |
| FY2022 | 27.5× | (56.19%) |
| FY2021 | 62.7× | — |
| FY2020 | 0.0× | — |
| FY2019 | 66.4× | 73.60% |
| FY2018 | 38.2× | 53.99% |
| FY2017 | 24.8× | 97.19% |
| FY2016 | 12.6× | 0.00% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 19.7× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PACB Pacific Biosciences of California, Inc. compare | n/m |
| CTKB Cytek Biosciences, Inc. compare | n/m |
| BBNX Beta Bionics, Inc. compare | n/m |
| AHCO AdaptHealth Corp. compare | n/m |
| LMRI Lumexa Imaging Holdings, Inc. compare | n/m |
| SIBN SiBone compare | n/m |
| QDEL QuidelOrtho Corporation compare | n/m |
| INMD InMode Ltd. compare | 11.3× |
| VREX VAREX IMAGING | 34.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)